Bessemer Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bessemer Group’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3K	Buy	102 +61	+149%	+$2.02K	﹤0.01%	2315
2025 Q4	$1K	Buy	+41	New	+$1.32K	﹤0.01%	2469
2021 Q2	–	Sell	-163	Closed	-$13K	–	1597
2021 Q1	$13K	Buy	+163	New	+$15K	﹤0.01%	1256
2020 Q4	–	Sell	-284,210	Closed	-$40.3M	–	1494
2020 Q3	$40.3M	Buy	284,210 +51,973	+22%	+$8.66M	0.12%	165
2020 Q2	$45.8M	Hold	232,237	–	–	0.14%	145
2020 Q1	$45.5M	Sell	232,237 -39,110	-14%	-$8.42M	0.18%	134
2019 Q4	$56.1M	Sell	271,347 -83,219	-23%	-$15.4M	0.18%	138
2019 Q3	$54.1M	Sell	354,566 -21,196	-6%	-$3.47M	0.19%	138
2019 Q2	$48.4M	Buy	+375,762	New	+$44.6M	0.16%	150

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bessemer Group's LKFT Position: Q1 2026 in Review

Bessemer Group increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 149% in Q1 2026, buying an estimated $2.02K and bringing the position to 102 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Bessemer Group first reported a position in LKFT in Q2 2019 and has held it in 9 quarters since. The position peaked at $56.1M in Q4 2019. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

Bessemer Group held 102 shares of Lakefront Biotherapeutics American Depositary Shares worth $3K as of Q1 2026.
Bessemer Group bought 61 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $2.02K.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2315 holding.
Bessemer Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2019 and has held it in 9 quarters since.
Bessemer Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $56.1M in Q4 2019.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.